Bexorg, Inc.

Bexorg, Inc. is a US-based company specializing in advanced technologies for drug discovery and development, particularly focused on addressing central nervous system disorders through innovative modeling solutions. Founded in 2021 by Zvonimir Vrselja (CEO) and Nenad Sestan and and headquartered in Connecticut, US, Bexorg, Inc. focuses on drug discovery solutions.

In January 2026, Bexorg, Inc. raised an undisclosed amount of grant funding from new investor Michael J. Fox Foundation. The company will use the funding to identify translational biomarkers for TRPML1-targeted therapies using its BrainEx postmortem whole-human brain platform.

The founder's previous experience is not documented. Bexorg, Inc. specializes in innovative solutions for drug discovery and development, specifically targeting central nervous system (CNS) disorders. At the core of their offerings is the BrainEx platform, which utilizes donated human brains to restore molecular activity, creating a translational model that provides clinically predictive data.

This platform aims to address the high failure rates of CNS clinical trials by offering a sophisticated alternative to traditional model systems, thereby accelerating the development of therapies for patients in urgent need. The company serves a diverse range of clients, including pharmaceutical firms and biotechnology companies, primarily in North America and Europe. Through its unique approach, Bexorg is positioned to significantly enhance the understanding of CNS pharmacology and therapeutic intervention, ultimately aiming to redefine treatment strategies for neurological diseases. Bexorg, Inc.

generates revenue through strategic partnerships and direct collaborations with pharmaceutical and biotechnology companies seeking to advance their drug development initiatives. The company’s transactions are predominantly structured as B2B agreements, where clients access the BrainEx platform for a fee, enabling them to leverage its capabilities for drug testing and validation. These agreements may involve both upfront payments and milestone-based fees contingent upon the successful advancement of drug programs. By providing access to their proprietary technology, Bexorg not only facilitates accelerated research and development but also enhances the likelihood of successful clinical outcomes for their partners.

The company's flagship platform is instrumental in creating pathways for effective drug delivery and disease modeling, establishing Bexorg as a key player in the evolving landscape of CNS therapeutics. The company will use the October 2025 funding to strengthen partnerships and advance its central nervous system programs.